Comment
Author: Admin | 2025-04-28
And Abilify (2 mg, 5 mg, 10 mg, 15 mg). While neither drug was significantly more effective for reduction of symptoms compared to the other, weight gain was listed as a common adverse effect among those taking Invega ER.This means that at least 10% of Invega ER users experienced weight gain, whereas this effect was not noted among those taking Abilify. The results from this study suggest that weight gain may be much more common for users of Invega ER than Abilify. It could be due to increased dopaminergic action compared to Abilify’s partial agonist effect at the D2 receptor.Source: http://www.ncbi.nlm.nih.gov/pubmed/256172532014: A total of 311 adults diagnosed with schizophrenia or schizoaffective disorder were assigned to receive injections of Haldol Decanoate (25 mg to 200 mg) or Invega Sustenna (39 mg to 234 mg) every month for up to 2 years. There wasn’t a significant difference in efficacy nor treatment failure when comparing the two drugs. However, it was noted that individuals receiving Invega Sustenna gained weight after 6 months, whereas those receiving Haldol Decanoate actually lost weight (on average).The reported weight gain caused by Invega Sustenna was approximately 4.78 lbs, whereas the loss on Haldol Decanoate was 2.11 lbs. Further, those receiving Invega Sustenna had significantly greater levels of prolactin – a hormone associated with weight gain. While weight gain was modest among those receiving Invega Sustenna, the prolactin increase may be more of a concern.Source: http://www.ncbi.nlm.nih.gov/pubmed/248460352013: A publication noted that atypical antipsychotics are thought to cause less side effects
Add Comment